Osmotica Pharmaceutical Corp is recalling approximately 19,983 bottles of Methylphenidate Hydrochloride Extended-release Tablets (the generic version of Concerta), used to treat ADHD. This recall includes both 27 mg and 54 mg dosage strengths sold in 100-count bottles under the Trigen Laboratories label. The medication is being recalled because it is subpotent, meaning the tablets may not contain the full amount of active medicine required, which can lead to reduced effectiveness in managing symptoms. Consumers should contact their healthcare provider or pharmacist to discuss alternative treatments and return the affected product to their pharmacy.
The tablets are subpotent and do not meet the required strength specifications, which may result in patients receiving a lower dose than prescribed. This can cause a failure to control symptoms of ADHD, such as inattention, impulsivity, or hyperactivity.
Contact healthcare provider or pharmacist and return for refund.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.